Login to Your Account



Kalbe switches focus to biosimilars from generics as Indonesia launches new regs

By Cornelia Zou
Staff Writer

Wednesday, January 22, 2014

HONG KONG – Biosimilars are in the spotlight in Indonesia after the government introduced new regulations and one of the largest pharmaceutical companies in Southeast Asia based there said it would consider making this category of drugs its focus going forward.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription